UnitedHealth, CVS, Cigna Accuse FTC Chair Khan of Serious Bias Against PBMs
Allegations of Bias Against PBMs
UnitedHealth, CVS, and Cigna have come forward, raising accusations against FTC Chair Khan for exhibiting serious bias against Pharmacy Benefit Managers (PBMs). They are requesting that FTC commissioners recuse themselves from the ongoing case, arguing that this bias could impede a fair outcome.
The Stakes for Healthcare Regulations
This confrontation highlights significant concerns regarding the regulation of the healthcare sector and the implications for pharmaceutical pricing. As the scrutiny over PBMs continues to grow, the underlying issues of market dynamics and healthcare costs remain pivotal for stakeholders.
Key Moments
- UnitedHealth's Intervention: UnitedHealth's strong stance emphasizes their position in the pharmaceutical landscape.
- CVS Health's Support: CVS adds weight to the claims, signaling a collective urgency among major players.
- Cigna's Participation: Cigna’s involvement underscores the broad implications for PBMs in regulatory discussions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.